Brief: Quantum Genomics Announces End Of Patient Recruitment For Phase III Pivotal Study FRESH

Quantum Genomics SA

09/05/2022 17:03

May 9 (Reuters) - Quantum Genomics SA  ALQGC.PA :
    * QUANTUM GENOMICS ANNOUNCES THE END OF PATIENT RECRUITMENT
FOR
ITS PHASE III PIVOTAL STUDY FRESH
    * NO TREATMENT-RELATED SERIOUS ADVERSE EVENT HAS YET BEEN
REPORTED
    * PHASE III PIVOTAL STUDY FRESH AIMS TO EVALUATE
FIRIBASTAT'S
EFFICACY IN TREATMENT OF DIFFICULT-TO-TREAT AND RESISTANT
HYPERTENSION
    * INITIAL RESULTS OF PHASE III PIVOTAL STUDY FRESH ARE
EXPECTED IN
LATE OCTOBER 2022
    * REFRESH IS CONTINUING NORMALLY, PROVIDING CONFIRMATION
THAT
MARKETING AUTHORIZATION APPLICATION WILL BE SUBMITTED IN Q3 OF
2023

Source text for Eikon:  ID:nGNX3jDYsP 
Further company coverage:  ALQGC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))